Knowledge center

The place to find all the most innovative research and information on novel biologics and biosimilars.


Polpharma Biologics announces approval of Europe’s first and only biosimilar for multiple sclerosis - Tyruko® (natalizumab)

Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.


You can find all the latest presentations, brochures and fact sheets below covering our solutions and portfolio.

Let’s collaborate and deliver quality biosimilars together.

Get in touch for more information.